Compare CRSP & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | ACLS |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | Switzerland | United States |
| Employees | 393 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.8B |
| IPO Year | 2016 | 2000 |
| Metric | CRSP | ACLS |
|---|---|---|
| Price | $51.20 | $144.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 4 |
| Target Price | $70.29 | ★ $101.50 |
| AVG Volume (30 Days) | ★ 1.6M | 559.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $289,590,000.00 | ★ $839,048,000.00 |
| Revenue This Year | $807.72 | $1.93 |
| Revenue Next Year | $172.52 | $7.91 |
| P/E Ratio | ★ N/A | $472.90 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $65.64 |
| 52 Week High | $78.48 | $193.78 |
| Indicator | CRSP | ACLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 44.54 |
| Support Level | $47.92 | $130.15 |
| Resistance Level | $59.61 | $147.94 |
| Average True Range (ATR) | 3.39 | 11.03 |
| MACD | -0.83 | -3.20 |
| Stochastic Oscillator | 12.78 | 31.93 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.